All Fulcrum Publications

March 3, 2024

Losmapimod, a p38 Small Molecule Inhibitor, Selectively Inhibits the DUX4 Program Without Negatively Impacting Myogenesis in FSHD

Genevieve Wilson, Erin Valentine, Joseph Maglio, Anthony Accorsi, Alejandro Rojas and Jeff Jacobs

March 1, 2024

Facioscapulohumeral Muscular Dystrophy European Patient Survey: Assessing Patient Reported Disease Burden and Preferences in Clinical Trial Participation

Megan M McNiff, Sheila Hawkins, Bine Haase, Joanne Bullivant, Tammy McIver, Olga Mitelman, Nicholas Emery, Giorgio Tasca, Nicol Voermans, Jordi Diaz-Manera

December 11, 2023

Single-cell transcriptome analyses further elucidate the mechanism of action of EED inhibition on HbF induction

Summer Xia Han, Emily Fitz, Allysa Allen, Avik Choudhuri, Caroline V. Sartain, Paul A. Bruno, Jeffrey W. Jacobs, Billy Stuart

October 3, 2023

Safety and Tolerability Data with Losmapimod in FSHD

M-H Jouvin, V Ramana, J Jiang

October 3, 2023

A Systematic Literature Review to Assess the Level of Evidence in Facioscapulohumeral Muscular Dystrophy

L Barnieh, R Beckerman, H Emich, K Eichinger, A Eldar-Lissai

June 15, 2023

Development of the HealthMeasures Facioscapulohumeral Muscular Dystrophy-32 (HM FSHD-32) Patient-Reported Outcome Measure

Shaunfield S, K Kaiser, CN Hurt, GJ Greene, D Peipert, A Eldar-Lissai, D Cella

May 7, 2023

APPLYING MACHINE LEARNING (ML) TO ESTIMATE THE PREVALENCE OF FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY (FSHD) AND RELATED DISEASE BURDEN; FINDINGS FROM UNITED STATES CLAIMS ANALYSIS

Winnen A, S Srivatsa, A Eldar‐Lissai, I Kouchlev, G Jones, T Zuroske

April 22, 2023

Design of REACH: Phase 3 Randomized, Double-Blind, Placebo-Controlled, 48-Week Study of the Efficacy and Safety of Losmapimod in FSHD

Tawil R, J Han, L Wang, J Vissing, J Statland, J Jiang

April 22, 2023

Muscle Ultrasound in an Open-Label Study of Losmapimod in Subjects with FSHD1

Kools J, N Voermans, K Mul, J Jiang, M Karlsson

March 19, 2023

Results from 96 Weeks of Dosing from the Open-Label Extension of a Phase 2 Trial of Losmapimod in Subjects with FSHD: ReDUX4

Wang L, J Han, J Jiang, R Tawil